日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Outcomes of a prospective cohort study of PREoperative therapy and supportive care in early & locally advanced breast cancers-PreSCella study

一项关于早期和局部晚期乳腺癌术前治疗和支持性护理的前瞻性队列研究的结果——PreSCella 研究

Lee, Han Yi; Ong, Whee Sze; Tan, Jasmine Yun Ting; Ma, Jun; Zhang, Zewen; Tan, Si Ying; Yang, Grace Meijuan; Teo, Irene; Goh, Wei Lin; Tan, Mabel May Leng; Yap, Yoon Sim; Chan, Jack Junjie; Tan, Ryan Shea Ying Cong; Tan, Wu Meng; Lim, Elaine; Sivaraj, Huren; Beh, Sok Yuen; Soh, Lay Tin; Chay, Wen Yee; Dent, Rebecca; Kanesvaran, Ravindran; Wong, Mabel; Tan, Benita Kiat Tee; Wong, Fuh Yong; Tan, Kiak Mien Veronique; Tan, Tira J

Comprehensive benchmarking of methods for mutation calling in circulating tumor DNA

对循环肿瘤DNA突变检测方法进行全面基准测试

Carrié, Hanaé; Sim, Ngak Leng; Wong, Pui Mun; Gan, Anna; Lau, Yi Ting; Poon, Polly; Thangaraju, Saranya; Tan, Iain; Yap, Yoon Sim; Krishnamachari, Kiran; Wong, Limsoon; Skanderup, Anders

Oncogenic non-V600 mutations evade the regulatory machinery of RAF including the Cdc37/Hsp90 chaperone and the 14-3-3 scaffold

致癌非 V600 突变逃避 RAF 的调节机制,包括 Cdc37/Hsp90 分子伴侣和 14-3-3 支架

Xiaoyu Wan, Jiajun Yap, Junjun Chen, Yifan Li, Regina Faruk, Nazereth Chor Boon Tan, Yiying Ma, Yiting Lim, Karlina Bte Jubri, Jingyi Hu, Jimin Yuan, Ge Zhang, Quan Li, Yoon Sim Yap, Paula Lam, Mei Wang, Nai Yang Fu, Jiancheng Hu

Sd-021, derivatives of decursin, inhibits tumorigenesis in NSCLC by inhibiting the EGFR/STAT3 signaling pathway.

Sd-021 是 decursin 的衍生物,它通过抑制 EGFR/STAT3 信号通路来抑制 NSCLC 的肿瘤发生

Hwang Hyun-Ha, Je Jeong-Hui, Lee Hyeong-Chan, Yoo Ji-Sung, Kim Taehyoun, Choi Jung Hwan, Hong Jin Won, Lim Hae-In, Kim Ga Yoon, Sim Yun-Beom, Cho Kwang-Jin, Choi Eun-Wook, Cheon Chunhoo, Lee Jae Yeol, Ko Seong-Gyu

Risking arm lymphedema in more than a hundred patients to benefit one patient-is it worth it?

为了让一名患者受益,冒着让一百多名患者患上手臂淋巴水肿的风险——值得吗?

Lim, Geok Hoon; Yap, Yoon-Sim; Lim, Rui Jun; Leong, Lester Chee Hao

Final Results of RIGHT Choice: Ribociclib Plus Endocrine Therapy Versus Combination Chemotherapy in Premenopausal Women With Clinically Aggressive Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer

RIGHT Choice 最终结果:瑞博西尼联合内分泌治疗与联合化疗治疗绝经前临床侵袭性激素受体阳性/人表皮生长因子受体 2 阴性晚期乳腺癌患者的疗效比较

Lu, Yen-Shen; Mahidin, Eznal Izwadi Bin Mohd; Azim, Hamdy; Eralp, Yesim; Yap, Yoon Sim; Im, Seock-Ah; Rihani, Julie; Gokmen, Erhan; El Bastawisy, Ahmed; Karadurmus, Nuri; Lim, Yueh Ni; Lim, Chun Sen; Duc, Le Thanh; Chung, Wei-Pang; Babu, K Govind; Penkov, Konstantin; Bowles, James; Alfaro, Teresa Delgar; Wu, Jiwen; Gao, Melissa; Slimane, Khemaies; El Saghir, Nagi S

Intrinsic Subtype and Overall Survival of Patients with Advanced HR+/HER2- Breast Cancer Treated with Ribociclib and ET: Correlative Analysis of MONALEESA-2, -3, -7

接受瑞博西尼和内分泌治疗的晚期 HR+/HER2- 乳腺癌患者的内在亚型和总生存期:MONALEESA-2、-3、-7 的相关性分析

Prat, Aleix; Solovieff, Nadia; André, Fabrice; O'Shaughnessy, Joyce; Cameron, David A; Janni, Wolfgang; Sonke, Gabe S; Yap, Yoon-Sim; Yardley, Denise A; Partridge, Ann H; Thuerigen, Astrid; Zarate, Juan Pablo; Lteif, Agnes; Su, Fei; Carey, Lisa A

A phase 3 study (PATHWAY) of palbociclib plus tamoxifen in patients with HR-positive/HER2-negative advanced breast cancer

一项针对HR阳性/HER2阴性晚期乳腺癌患者的帕博西尼联合他莫昔芬的3期研究(PATHWAY)

Noguchi, Emi; Yamanaka, Takashi; Mukai, Hirofumi; Yamamoto, Naohito; Chung, Chi-Feng; Lu, Yen-Shen; Chang, Dwan-Ying; Sohn, Joohyuk; Kim, Gun Min; Lee, Kyung-Hun; Lee, Soo-Chin; Iwasa, Tsutomu; Iwata, Hiroji; Watanabe, Kenichi; Jung, Kyung Hae; Tanabe, Yuko; Kang, Seok Yun; Yasojima, Hiroyuki; Aogi, Kenjiro; Tokunaga, Eriko; Sim, Sung Hoon; Yap, Yoon Sim; Matsumoto, Koji; Tseng, Ling-Ming; Umeyama, Yoshiko; Sudo, Kazuki; Kojima, Yuki; Hata, Tomomi; Kuchiba, Aya; Shibata, Taro; Nakamura, Kenichi; Fujiwara, Yasuhiro; Tamura, Kenji; Yonemori, Kan

Exploiting metabolic vulnerabilities in breast cancers with NF1 loss

利用NF1缺失乳腺癌的代谢脆弱性

Yap, Yoon-Sim; Hu, Jiancheng

Potential value of ctDNA monitoring in metastatic HR + /HER2 - breast cancer: longitudinal ctDNA analysis in the phase Ib MONALEESASIA trial

ctDNA监测在转移性HR+/HER2-乳腺癌中的潜在价值:Ib期MONALEESASIA试验中的纵向ctDNA分析

Chiu, Joanne; Su, Fei; Joshi, Mukta; Masuda, Norikazu; Ishikawa, Takashi; Aruga, Tomoyuki; Zarate, Juan Pablo; Babbar, Naveen; Balbin, O Alejandro; Yap, Yoon-Sim